Company intelligence / Profile preview

Evrys Bio

King of Prussia, Pennsylvania, United Statesevrysbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Evrys Bio has demonstrated excellent preclinical activity of proprietary sirtuin-targeting small molecules against a range of viruses including coronaviruses and influenza. The company has received significant non-dilutive funding to advance these candidates toward the clinic, with a focus on broad-spectrum antivirals that reduce the risk of drug resistance.[4][5] No published human clinical results yet.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (sirtuin modulators)[1][2][3]
Industry: Biotech

Drug pipeline

2 assets

EV-100

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

U.S. Department of Defense ($34M contract for development of broad-spectrum antivirals)[4]

Beyond the preview

Go deeper on Evrys Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evrys Bio.

Explore the full profile